Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.13
BEAT's Cash-to-Debt is ranked lower than
65% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. BEAT: 0.13 )
Ranked among companies with meaningful Cash-to-Debt only.
BEAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 209.11 Max: No Debt
Current: 0.13
Equity-to-Asset 0.51
BEAT's Equity-to-Asset is ranked higher than
68% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BEAT: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
BEAT' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.16  Med: 0.77 Max: 0.92
Current: 0.51
-1.16
0.92
Debt-to-Equity 0.79
BEAT's Debt-to-Equity is ranked higher than
62% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. BEAT: 0.79 )
Ranked among companies with meaningful Debt-to-Equity only.
BEAT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.49  Med: 0.18 Max: 0.79
Current: 0.79
-1.49
0.79
Debt-to-EBITDA 7.02
BEAT's Debt-to-EBITDA is ranked higher than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. BEAT: 7.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BEAT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01  Med: 0.61 Max: 7.02
Current: 7.02
0.01
7.02
Interest Coverage 1.26
BEAT's Interest Coverage is ranked lower than
87% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. BEAT: 1.26 )
Ranked among companies with meaningful Interest Coverage only.
BEAT' s Interest Coverage Range Over the Past 10 Years
Min: 0.11  Med: 8.03 Max: No Debt
Current: 1.26
Piotroski F-Score: 4
Altman Z-Score: 2.15
Beneish M-Score: -1.02
WACC vs ROIC
7.59%
25.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.59
BEAT's Operating Margin % is ranked higher than
62% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BEAT: 3.59 )
Ranked among companies with meaningful Operating Margin % only.
BEAT' s Operating Margin % Range Over the Past 10 Years
Min: -51.52  Med: -3.95 Max: 8.65
Current: 3.59
-51.52
8.65
Net Margin % 16.10
BEAT's Net Margin % is ranked higher than
96% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. BEAT: 16.10 )
Ranked among companies with meaningful Net Margin % only.
BEAT' s Net Margin % Range Over the Past 10 Years
Min: -51.61  Med: -5.77 Max: 25.65
Current: 16.1
-51.61
25.65
ROE % 25.49
BEAT's ROE % is ranked higher than
98% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. BEAT: 25.49 )
Ranked among companies with meaningful ROE % only.
BEAT' s ROE % Range Over the Past 10 Years
Min: -57.69  Med: -13.67 Max: 49.75
Current: 25.49
-57.69
49.75
ROA % 15.50
BEAT's ROA % is ranked higher than
97% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. BEAT: 15.50 )
Ranked among companies with meaningful ROA % only.
BEAT' s ROA % Range Over the Past 10 Years
Min: -48.81  Med: -8.74 Max: 33.07
Current: 15.5
-48.81
33.07
ROC (Joel Greenblatt) % 23.12
BEAT's ROC (Joel Greenblatt) % is ranked higher than
82% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. BEAT: 23.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BEAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -195.03  Med: -24.05 Max: 56.73
Current: 23.12
-195.03
56.73
3-Year Revenue Growth Rate 10.50
BEAT's 3-Year Revenue Growth Rate is ranked higher than
65% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. BEAT: 10.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BEAT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -41  Med: 0.6 Max: 52.8
Current: 10.5
-41
52.8
3-Year EBITDA Growth Rate 70.70
BEAT's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. BEAT: 70.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BEAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.6 Max: 70.7
Current: 70.7
0
70.7
GuruFocus has detected 3 Warning Signs with BioTelemetry Inc BEAT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BEAT's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BEAT Guru Trades in Q4 2016

Jim Simons 1,099,300 sh (+7.02%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 319,409 sh (-33.00%)
» More
Q1 2017

BEAT Guru Trades in Q1 2017

Jim Simons 1,247,045 sh (+13.44%)
Chuck Royce 212,409 sh (-33.50%)
» More
Q2 2017

BEAT Guru Trades in Q2 2017

Jim Simons 1,085,600 sh (-12.95%)
Chuck Royce 177,409 sh (-16.48%)
» More
Q3 2017

BEAT Guru Trades in Q3 2017

Joel Greenblatt 19,730 sh (New)
Chuck Royce 191,391 sh (+7.88%)
Jim Simons 953,400 sh (-12.18%)
» More
» Details

Insider Trades

Latest Guru Trades with BEAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 New Buy0.01%$29.95 - $38.45 $ 25.50-26%19,730
Joel Greenblatt 2016-12-31 Sold Out 0.01%$15.35 - $23.35 $ 25.5030%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8093
Compare:NSE:LALPATHLAB, TSE:4694, SZSE:300396, NAS:NRCIA, NAS:ALOG, NAS:KANG, HKSE:02393, TSE:4282, NAS:AXDX, NAS:ABAX, SHSE:603127, SZSE:300685, NAS:GHDX, NAS:LNTH, SZSE:300289, SZSE:300439, NAS:HSKA, SZSE:300639, OSTO:SECT B, NAS:NEO » details
Traded in other countries:C25.Germany,
Headquarter Location:USA
BioTelemetry Inc provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Its segments are healthcare, technology and research.

BioTelemetry Inc provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Its segments are healthcare, technology and research.

Ratios

vs
industry
vs
history
PE Ratio 19.46
BEAT's PE Ratio is ranked higher than
77% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. BEAT: 19.46 )
Ranked among companies with meaningful PE Ratio only.
BEAT' s PE Ratio Range Over the Past 10 Years
Min: 11.34  Med: 35.69 Max: 916.88
Current: 19.46
11.34
916.88
Forward PE Ratio 19.19
BEAT's Forward PE Ratio is ranked higher than
52% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. BEAT: 19.19 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.46
BEAT's PE Ratio without NRI is ranked higher than
78% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. BEAT: 19.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
BEAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.34  Med: 35.69 Max: 916.88
Current: 19.46
11.34
916.88
Price-to-Owner-Earnings 24.85
BEAT's Price-to-Owner-Earnings is ranked higher than
66% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. BEAT: 24.85 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BEAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.23  Med: 30.75 Max: 115.99
Current: 24.85
12.23
115.99
PB Ratio 3.14
BEAT's PB Ratio is ranked lower than
72% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. BEAT: 3.14 )
Ranked among companies with meaningful PB Ratio only.
BEAT' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.03 Max: 6.99
Current: 3.14
0.42
6.99
PS Ratio 3.21
BEAT's PS Ratio is ranked lower than
59% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. BEAT: 3.21 )
Ranked among companies with meaningful PS Ratio only.
BEAT' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.43 Max: 5.22
Current: 3.21
0.43
5.22
Price-to-Free-Cash-Flow 89.16
BEAT's Price-to-Free-Cash-Flow is ranked lower than
76% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. BEAT: 89.16 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BEAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.18  Med: 29.54 Max: 1795.71
Current: 89.16
5.18
1795.71
Price-to-Operating-Cash-Flow 34.46
BEAT's Price-to-Operating-Cash-Flow is ranked lower than
71% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. BEAT: 34.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BEAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.64  Med: 20.93 Max: 1145
Current: 34.46
3.64
1145
EV-to-EBIT 109.64
BEAT's EV-to-EBIT is ranked lower than
88% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. BEAT: 109.64 )
Ranked among companies with meaningful EV-to-EBIT only.
BEAT' s EV-to-EBIT Range Over the Past 10 Years
Min: -1960.8  Med: -0.7 Max: 327.4
Current: 109.64
-1960.8
327.4
EV-to-EBITDA 34.38
BEAT's EV-to-EBITDA is ranked lower than
77% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. BEAT: 34.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
BEAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -164.2  Med: 17.6 Max: 447.9
Current: 34.38
-164.2
447.9
EV-to-Revenue 4.04
BEAT's EV-to-Revenue is ranked lower than
57% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. BEAT: 4.04 )
Ranked among companies with meaningful EV-to-Revenue only.
BEAT' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 1.4 Max: 9.4
Current: 4.04
0.1
9.4
Current Ratio 1.60
BEAT's Current Ratio is ranked lower than
62% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. BEAT: 1.60 )
Ranked among companies with meaningful Current Ratio only.
BEAT' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.34 Max: 7.88
Current: 1.6
0.44
7.88
Quick Ratio 1.48
BEAT's Quick Ratio is ranked lower than
56% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BEAT: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
BEAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.19 Max: 7.88
Current: 1.48
0.44
7.88
Days Inventory 17.52
BEAT's Days Inventory is ranked higher than
84% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. BEAT: 17.52 )
Ranked among companies with meaningful Days Inventory only.
BEAT' s Days Inventory Range Over the Past 10 Years
Min: 5.61  Med: 12.9 Max: 19.72
Current: 17.52
5.61
19.72
Days Sales Outstanding 53.89
BEAT's Days Sales Outstanding is ranked higher than
90% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. BEAT: 53.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
BEAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.57  Med: 65.49 Max: 119.19
Current: 53.89
25.57
119.19
Days Payable 53.50
BEAT's Days Payable is ranked lower than
68% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. BEAT: 53.50 )
Ranked among companies with meaningful Days Payable only.
BEAT' s Days Payable Range Over the Past 10 Years
Min: 30.45  Med: 54.23 Max: 65.87
Current: 53.5
30.45
65.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
BEAT's 3-Year Average Share Buyback Ratio is ranked higher than
67% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. BEAT: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BEAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -102  Med: -2.9 Max: -1.6
Current: -3.1
-102
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.05
BEAT's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. BEAT: 3.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BEAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 4.37 Max: 7.16
Current: 3.05
0.87
7.16
Price-to-Median-PS-Value 2.28
BEAT's Price-to-Median-PS-Value is ranked lower than
95% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BEAT: 2.28 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BEAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 0.96 Max: 3.59
Current: 2.28
0.33
3.59
Earnings Yield (Greenblatt) % 0.93
BEAT's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. BEAT: 0.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BEAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -585.6  Med: -2.4 Max: 9.1
Current: 0.93
-585.6
9.1

More Statistics

Revenue (TTM) (Mil) $248.99
EPS (TTM) $ 1.31
Beta0.81
Short Percentage of Float6.73%
52-Week Range $18.60 - 39.20
Shares Outstanding (Mil)32.41

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 284 386 428 473
EPS ($) 0.90 1.26 1.90 2.45
EPS without NRI ($) 0.90 1.26 1.90 2.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
27.90%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}